ONTX – Looking For The Reversal Pattern

Onconova Therapeutics, Inc. (ONTX) -Nasdaq   Onconova has recently plunged about $19 from the 52-week high at $31.13, reached just a month ago to the current level in mid-$13s and reaching the.

Merck – Quick Chart Review

Merck & Co. Inc. (MRK) -NYSE For the first time since March 1st, MRK’s price dropped below its 200-Day Moving Average. This is worth a deeper look at the price action.

ACHN – In Consolidation Mode

Achillion Pharmaceuticals, Inc. (ACHN – Nasdaq) On  July 1, 2013 the FDA placed a clinical hold on Achillion’s hep C drug and the shares plunged 22% from $8.36 to $6.17 the.

PGNX – Preparing For The Next Run

Progenics Pharmaceuticals, Inc. (PGNX) -Nasdaq Since my latest “Chart & TA” report “PGNX – A Hidden Bullish Divergence” on Aug 22nd, 2013. PGNX  has been trading up and gained 33% in just.

AMRN – Another Breakout – Chart Update

Amarin Corporation plc (AMRN) -Nasdaq Since my latest “Chart & TA” report AMRN – Running Up To The AdCom on Aug 30th, 2013. AMRN kept trading up and gained 4.7% , reaching.

RPTP – New All Time High

Raptor Pharmaceuticals Corp. (RPTP) -Nasdaq Opportunity knocks all the time, but you have to be ready for it. If the chance comes, you must be ready and quickly respond to take.

AMRN – Running Up To The AdCom

Amarin Corporation plc (AMRN) -Nasdaq The price closed above the 100-Day moving avarage and the $6.34 resistance line, while the indicators still positive and wants more upside. The next important line to.

PGNX – A Hidden Bullish Divergence

Progenics Pharmaceuticals, Inc. (PGNX) -Nasdaq On June 11, 2013 Progenics and Salix (partner) announced an FDA Advisory Committee (AdCom) is scheduled to review Relistor sNDA for opioid-induced constipation(OIC) in patients with.

IBB – Technical Commentary

iShares Nasdaq Biotechnology (IBB) – Nasdaq The best indicators for our biotech portfolio are the biotechnology indices IBB, NBI, XBI or XLV. After publishing “IBB – Biotechnology Index at All Times.

ASTX – Breaking out of the Downtrend Channel

Astex Pharmaceuticals, Inc. (ASTX)  -Nasdaq ASTX had an epic run that started at the end of February from the low of $2.94, just after two months of price consolidation, and reached.

BMY – In A Consolidation Mode

Bristol-Myers Squibb Company (NYSE: BMY) BMY had an amazing run ahead of ASCO-2013 that left many well-planned traders very happy. The stock found strong support near the 50-Day Moving Average.

SRPT – Sarepta – Is It The Time For A New High?

Sarepta Therapeutics, Inc – Nasdaq(SRPT) Sarepta is one of the most followed tickers in twitterville with a real bulls/bears debate. It has strong moms’ advocacy groups fighting full strength to get.

IBB – Biotechnology Index at All Times High

Nasdaq Biotechnology Index Fund ETF (IBB) The best indicator for our biotech portfolio are the biotechnology indexes like IBB, NBI, XBI or XLV. Since we already published “The IBB and.

SRPT – A Quick Look At The Chart

Sarepta Therapeutics, Inc – Nasdaq(SRPT) Quick update: A big drop in SRPT today leaving the traders with speculation that there could be a leak about the decision to file for accelerated.

DCTH – Soaring Ahead of The Upcoming Advisory Committee

Delcath Systems, Inc. (DCTH) -Nasdaq DCTH has been on our watch list for a while, looking for an entry point. we kept following out the stock performance at the forum and.

XNPT – It’s Time to Join The Run To The Ph-3 Resutls

Xenoport, Inc. (XNPT) -Nasdaq Lately, the reals runner were those with pending clinical trial data, where we saw TSRX and ZIOP’s share price move much more than the PDUFA runners..

SGMO – Is it The Time For a Correction

Sangamo Biosciences Inc. (SGMO) -Nasdaq Within three months the share price of SGMO doubled, soaring from the $5.50 area and reaching a new 5 years high of  $11.24, getting a.

ZIOP – Preparing for an Explosive Move

ZIOPHARM Oncology, Inc. (ZIOP)-Nasdaq Since November 11, 2012 ZIOP was trading in a horizontal channel, the upper resistance line at $4.81 and the lower support line at $4.01, till February.

DEPO – Action Ahead Of The AdCom

DepoMed Inc. (DEPO) -Nasdaq Serada is an investigational formulation of gabapentin, an FDA-approved immediate release pharmaceutical for the treatment of partial epilepsy and management of postherpetic neuralgia (PHN). Recently published.

SRPT – Preparing For The Next Move

Sarepta Therapeutics, Inc. (SRPT)-Nasdaq Sarepta is a biotech company under the spotlights since early October 2012, after presenting strong Phase IIb results for the compound Eteplirsen in the treatment of.

Browsing 20 / articles